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Background: Malignant melanoma is a less common but highly dangerous form of skin cancer; it starts in the
melanocytes cells found in the outer layer of the skin. Jararhagin toxin, a metalloproteinase isolated from Bothrops
jararaca snake venom acts upon several biological processes, as inflammation, pain, platelet aggregation, proliferation
and apoptosis, though not yet approved for use, may one day be employed to treat tumors.
Methods: B16F10 murine melanoma cells were treated with jararhagin (jara), a disintegrin-like metalloproteinase
isolated from Bothrops jararaca snake venom, and jari (catalytic domain inactivated with 1,10-phenanthroline). Viability
and adhesion cells were evaluated by MTT assay. The expression of caspase-3 active, phases of the cell cycle and
apoptosis were assessed by flow cytometry. We analyze in vivo the effects of jararhagin on melanoma growth,
apoptosis and metastasis.
Results: The tumor cells acquired round shapes, lost cytoplasmic expansions, formed clusters in suspension and
decreased viability. Jari was almost 20 times more potent toxin than jara based on IC50 values and on morphological
changes of the cells, also observed by scanning electron microscopy. Flow cytometry analysis showed 48.3% decrease
in the proliferation rate of cells and 47.2% increase in apoptosis (jara) and necrosis (jari), following 1.2 μM jara and 0.1
μM jari treatments. Caspase-3 activity was increased whereas G0/G1 cell cycle phase was on the decline. Proliferative
rate was assessed by staining with 5,6-carboxyfluoresceindiacetate succinimidyl ester, showing a significant decrease in
proliferation at all concentrations of both toxins.
Conclusions: In vivo treatment of the toxins was observed reduction in the incidence of nodules, and metastasis and
antiproliferative inhibition capacity. This data strengthens the potential use jararhagin as an anti-neoplastic drug.
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Bothrops jararacaBackground
Murine and human melanoma cells have been extensively
used aiming at the evaluation of cellular and molecular
changes induced by toxins from different snake venom
metalloproteinases (SVMP). Effects on adhesion, migra-
tion and invasion of tumor cells through the extracellular
matrix in vitro, and decreased number of metastasis
in vivo were observed by a number of toxins, like eristos-
tatin [1-3]; echistatin [4,5]; contortrostatin [6-9]; salmo-
sin [10-12]; Vipera lebetina turanica whole venom [13];* Correspondence: durvanei.maria@butantan.gov.br
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unless otherwise stated.triflavin [14]; albolatrin [15]; and several others. Similar ef-
fects were demonstrated by oligopeptides whose design
was based on particular sequences of the disintegrin do-
main of metalloproteinases [16,17]. Jararhagin (jara), a
multidomain toxin isolated from the venom of Bothrops
jararaca, belongs to the PIII snake venom toxin family,
and presents a catalytic Zn-dependent metalloproteinase
domain, a disintegrin-like domain (ECD instead of RGD
motif), and a cystein-rich domain [18]. Jararhagin stimu-
lated migration and cytoskeleton rearrangement in normal
epithelial cells, and recruited αv, but not α2 integrins [19].
It is known that jara binds to collagen and to the α2β1
integrin through two independent motifs, located ontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ively [20].
The chelating compound 1,10-phenanthroline inhibits
Zn-dependent metalloproteinases, and was previously
used to inactivate the catalytic domain of jara. Costa and
Santos [19] showed inhibition on cells adhesion after
treatment with jara inactivated with 1,10 orthophenantro-
line (jari). Accordingly, SK-Mel-28 human melanoma cells
treated in vitro with jara or jari inhibited cells adhesion,
besides inhibitory effects on morphology, proliferation
and viability of cells. However, tumor cells migration and
invasion were decreased in vitro, and a significant inhib-
ition of tumor nodules multiplicity was observed mice
genetically selected for acute inflammatory response [21].
Vitaxin (MEDI-522), a humanized antibody derived from
the mouse LM609 monoclonal antibody, was recently re-
ported to give positive results in a phase II trial enrolling
patients with stage IV metastatic melanoma [22].
In the present study, the B16F10 cell line, a highly
metastatic variant isolated from a spontaneous melan-
oma tumor from C57BL/6 J mouse [23], confirmed the
previous study using SK-Mel-28 human melanoma cells.
The effect of injection of B16F10 cells, pretreated with
jara and jari, on allograph tumor growth and metastases
in vivo was also investigated.Methods
Cell cultures
The B16F10 murine melanoma cell line was obtained
from American Type Culture Collection (Mannasa, VA,
USA). The cells were maintained in 25–75 cm3 flasks con-
taining RPMI-1640 medium (Sigma Chemical Co., St.
Louis, MO, USA) supplemented with 10% heat-inactivated
fetal bovine serum (Cultilab, Campinas, BR), 2 mM L-
glutamine (Sigma), 100 U/ml penicillin and streptomycin
(Fontoura Wyeth AS), in a humidified incubator at 5%
CO2 and 37°C. For growth assays, cells were cultured in
octuplicate using 96-wells flat bottom microplates (Nunc,
Int. Corp., Rochester USA) at 2 × 104 cells/well density.
Cells were harvested at near confluence with 0.2% trypsin
(Sigma) and counted for viability by trypan blue exclusion
assay using the Malassez chamber.Isolation of jara and inactivation of its catalytic domain (jari)
Crude venom (20 mg) was fractionated in a FPLC phenyl-
superose column, eluted, chromatographed on MonoQ
column (FPLC), and the 52 kDa toxin band corresponding
to jara was resolved on SDS-PAGE, and quantified by the
Bradford method, as described [24]. Inactivation of the
catalytic domain of jara was carried out through incuba-
tion with 10 mM 1,10-phenanthroline for 30 min at 37°C.
The altered toxin was subsequently named jari.MTT assay
Viability of B16F10 cells was evaluated using the MTT
[3-(4,5-dimethyl-thiazol-2-y1) 2,5-diphenyl tetrazolium
bromide] (Sigma Chemical Co., St. Louis, MO, USA) col-
orimetric assay, that is based on the reduction of formazan
crystals by living cells [25]. Briefly, B16F10 cells were
seeded in 96-well tissue culture plates at 2 × 104 cells per
well and incubated for 24 h. The cells were treated with
different concentrations of jara and jari (0.0005 to
1.2 μM); control cells were treated with PBS. Then,
plates were incubated at 37°C under 5% CO2 for 24 h.
After treatment, the supernatants were removed, 100 μL
of 5 mg/mL MTT solution was added to each well, and
the plate was incubated for 3 h. The precipitated formazan
crystals were diluted in DMSO (Sigma Chemical Co., St.
Louis, MO, USA) and measured at 540 nm using the mi-
croplate reader Thermo Plate (Rayto Life and Analytical
Science C. Ltd, Germany). The IC50 value, which repre-
sents the concentration of toxin needed to decrease viabil-
ity to 50%, as compared to untreated cells, was calculated
from the concentration-response curve. Morphological
changes induced on cells by jara and jari were observed
through inverted light microscopy (Carl Zeiss, Germany),
and the images were captured through CCD-IRIS, color
video camera (Sony Co.), Cyto Viewer Lite Program.
Cell adhesion assay
B16F10 cells were treated with jara (0.4 and 0.8 μM) and
jari (0.2 and 0.4 μM) as described for the MTTassay. After
24 h incubation, the medium was removed and the cells
were washed with 0.1 M PBS pH 7.2. Adherent cells were
fixed with 0.1% glutaraldehyde, washed in PBS, stained
with crystal violet 0.5% (Sigma Chemical Co., St. Louis,
MO, USA), washed and then eluted with 100% ethanol.
Absorbance was measured at 620 nm in ELISA counter
(Titertek Multiscan) using the microplate reader Thermo
Plate.
Proliferative index by CFSE-DA
Methods used to perform proliferation analysis using
CFSE-DA have been described previously [26]. Prolifera-
tion determination by CFSE-DA (5,6-carboxyfluores-
ceindiacetate succinimidyl ester) labelling method was
adapted from a previously described protocol [27] that
allows for direct detection of single proliferating cells,
and facilitates quantification of cell division by flow cy-
tometry, according to respective CFSE-dilution. Melan-
oma cells B16F10 treated with jara (0.4 and 0.8 μM) and
jari (0.2 and 0.4 μM) for 24 h were analysed. Positive con-
trol group of lymph nodes of normal C57BL/6 J mice were
cultured in RPMI-1640 medium supplemented with
2 mM L-glutamine (Cambrex, Belgium), 500 μM 2-
mercaptoethanol (Sigma Aldrich, Germany), 20% heat-
inactivated FCS and 1% penicillin/streptomycin (Cultilab,
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sions were cultured in U-bottom 96-well plates (Nunc,
Denmark) with either 15 μg/mL phytohaemagglutinin
(Sigma Aldrich, Germany) or medium alone. In each case
a pellet of 105 cells was resuspended in 1 ml of CFSE-DA
labelling solution with concentrations ranging from
10 μM to 37 nM and incubated for 15 min at 37°C in the
dark. After labelling, lymphocytes were incubated at 37°C
in a 5% CO2 incubator for 96 h. Samples were transferred
to flow cytometry tubes, and cells were counted using a
FACSCalibur™ (BD – USA) flow cytometer. CFSE flow cy-
tometric data files were analysed using Cell- QuestTM ac-
quisition/analysis software (Becton Dickinson, San Jose,
CA). Fifty thousand events were collected, and population
proliferation was analysed using ModFitLT 2.0 software
(Proliferation Wizard Methods).
Scanning electron microscopy (SEM)
B16F10 cells (5 × 105) treated with jara (0.4 and 0.8 μM)
and jari (0.2 and 0.4 μM) for 24 h were washed with PBS
and fixed in 2.5% glutaraldehyde pH= 7.2 at 4°C. Follow-
ing 24 h fixation, the cells were rinsed in Na3PO4 buffer
and were post fixed in 1% osmium tetroxide for 2 h at
4°C. Samples were dehydrated in increasing ethanol series,
immersed in isoamyl acetate and at a critical point dried
in liquid CO2 for 5 min. Samples were sputtered and
coated with gold metal and examined in the Leo 435VP
Zeiss scanning electron microscope (Carl Zeiss, Germany).
Caspase-3 active in B16F10 melanoma cells
Caspase-3 active was determined by flow cytometry after
treatment for 24 h with jara (0.4, 0.8, 1.2 μM), jari (0.1,
0.2, 0.4 μM), taxol 10 μM and untreated cells. Cells were
washed with PBS and incubated with 1 μg caspase-3-
specific antibody (Santa Cruz, USA) and with or without
caspase-3 inhibitor (Z-DEVD-FMK, Sigma). Samples
were incubated in a 5% CO2 incubator at 37°C for 1 h
before flow cytometry quantification. All experiments
were done through the FL2 channel by FACScalibur flow
cytometer (Beckton-Dickinson, San Jose, CA, USA), with
a minimum of 10,000 events acquired for each sample in
three independent experiments.
Apoptosis analysis by flow cytometry
B16F10 cells (2 × 105) were seeded in 6-well culture plates
and incubated at 37°C for 24 h. Cells were treated for 24 h
with jara (0.4 and 0.8 μM) and jari (0.2 and 0.4 μM); con-
trol cells were treated with PBS alone. Cells found in the
supernatant and adherent cells were incubated with spe-
cific binding buffer (10 mM Hepes, 140 mM NaCl,
2.5 mM CaCl2, pH = 7.4), containing 5 μL of annexin
V-FITC (Santa Cruz, USA) and 1.8 ug/mL propidium iod-
ide for 30 min at room temperature in the dark. After in-
cubation, 400 μL binding buffer was added and cells wereanalyzed with FACScalibur (Becton DicKinson) using
CellQuest software, determining the percentage of apop-
totic cells.
Cell cycle analysis
B16F10 cells were treated for 24 h with jara (0.4 and
0.8 μM) and jari (0.2 and 0.4 μM); control cells were
treated with PBS alone. Supernatant and adherent cells
were collected and washed in PBS. Cells and apoptotic
bodies were harvested by centrifugation at 3000 rpm for
10 min. The cell pellet was fixed in ice-cold ethanol 70%
and maintained overnight at −20°C. Prior analysis, PBS
containing 1.8 μg/mL propidium iodide (Sigma Chemical
Co., St. Louis, MO, USA) and 0.1 mg/L ribonuclease-A
(Sigma Chemical Co., St. Louis, MO, USA) was added to
the cell pellet and incubated in the dark for 20 min at
room temperature. At least 10,000 events were acquired
using CellQuest sotware. DNA content was measured in
the FL2 channel on FACScalibur flow cytometer (BD,
USA). The percentage of apoptotic cells and cells in the
cell cycle phases G0/G1, S, G2/M and sub-haploid cells
was determined using the ModFit 2.9 software.
Experimental metastasis assays in vivo
B16F10 cells were treated with jara (0.8 μM) or jari
(0.2 μM) during 24 h. Pretreated cells (5 × 104) were
injected subcutaneously in the dorsal region of each ani-
mal from three groups of 10 female C57BL/6 J mice. Un-
treated cells were injected in the control group. Mice were
fed daily with ration ad libitum and water, and were killed
40 days later by administration of anesthetics, 160 μL of
Ketamine hydrochloride was added to 400 μL of Xylazine,
the prepared anesthetic agents were administered by in-
traperitoneal injects to mice at a volume 100 μL/g of body
weight. The dorsal tumor developed at the site of injection
was measured and the mean tumor volume was calculated
[length (mm) × width2 (mm) × ¶/6)]. The ratio between
tumor volumes of animals injected with untreated (con-
trol) versus toxin-treated MM cells was used to calculate
toxin efficacy. Tumor tissues were removed and the num-
ber of metastatic lesions were quantified visually, mea-
sured, excised, fixed in 10% formalin and prepared for
histopathology analysis. The experiments were carried out
in accordance with the protocol of the Ethics Commission
of Butantan Institute (CEUAIB N° 638/09).
Cell cycle of lung metastasis cells
The metastases of lung were removed after necropsies
proceed and perfused immediately with 1 ml of ice-cold
enzyme solution [0.5 mg/ml deoxyribonuclease-I, 1 mg/
ml collagenase type IV (Boehringer Mannheim) and 0.1
U/ml elastase (Sigma) in Tyrode’s buffer] for 30 min in a
shaking water bath (250 rpm, 37°C). Cells released were
separated from the tissue by filtration (100 μm mesh
Figure 1 Analysis of cell viability after treatment with toxins in B16F10 melanoma cell. The viability of B16F10 melanoma cells was
determined by the MTT assay after 24 h treatment using varying concentrations of jara, jari, and the chelating agent 1,10-phenanthroline. The
viability curves regarding jara and jari treatments showed significant differences according to the Student unpaired t test (p < 0.05).
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twice in RPMI 1640 medium, the pellet was resuspended
in fresh medium and cell counts were determined using
the Malassez Chamber.Statistical analysis
Data were reported as mean ± standard deviation (SD),
expressed as percentage or optical density of cell viability,
adhesion in vitro; and number, incidence and mean vol-
ume of metastatic nodules. Statistical tests were per-
formed by Student unpaired t-test and non-parametric
Fisher’s-Yates exact tests (GraphPad Prism software, ver-
sion 5 for Windows, San Diego, CA, USA). A probability of
0.05 or less was deemed statistically significant. The fol-
lowing notation was used throughout the text: *p < 0.05,
**p < 0.01 and ***p < 0.001, relative to controls. The sur-
vival rates were calculated daily and the experiment was
terminated when all the mice of control group died. Sur-
vival rate data were analyzed by Kaplan-Meier curves.Figure 2 Cell adhesion assay 24 hours after treatment with
toxins in B16F10 melanoma cell. The percentage of adherent cells
after treatments was significantly different for jara and jari (p < 0.01)
using by Student unpaired t test. The results are representative of
three independent experiments.Results
Viability and adhesion effects of toxins treatment
The evaluation of jara and jari effects on B16F10 cell via-
bility by the MTT assay also showed a dose-dependent
cytotoxicity after 24 h. Concentrations equal or higher
than 0.4 μM jara and 0.01 μM jari induced severe cytotox-
icity that was statistically significant (*p < 0.05). According
to the B16F10 viability curve, the IC50 values for jara
and jari were 0.43 μM and 0.15 μM, respectively (Figure 1).
No toxicity was observed in cells treated with 1,10-
phenanthroline alone. In adhesion assays, concentrations
higher than 0.1 μM jara or 0.01 μM jari significantly de-
creased the B16F10 cells adhesion in a dose-dependent
manner (Figure 2).Determination of cell division rate following Jara and Jari
treatments in melanoma cells B16F10
Melanoma cells were labelled with CFSE-DA to be used
as control groups and were cultured for 24, 48 and 72 h;
after culture, cells were harvested and analysed by flow
cytometry. Cell division is characterized by sequential
halving of CFSE fluorescence, generating equally spaced
peaks on a logarithmic scale; peaks indicate the division
cycle number. Similar results of MTT colorimetric assay
were obtained using CSFE methodology, which accurately
confirmed rate of proliferation of melanoma cells, in dif-
ferent periods of treatment with Jara and Jari. Figure 3
presents histograms acquired using ModFitLT 2.0 soft-
ware and comparison of significant differences is shown in
Figure 3A, B, C and D. Proliferation index showed a sig-
nificant decrease in the population of melanoma cells at
all concentrations of both toxins.
Figure 3 Proliferative rate of B16F10 melanoma cells. Toxins inhibit the proliferation and induce cell cycle arrest in B16F10 cells. Proliferation
rates in B16F10 melanoma cells treated with jara and jari toxins for 24, 48 and 72 h determined using the ModFitLT 2.0 software. (A) The means
proliferative rate using CFSE-DA assay of jara group; (B) CFSE-DA proliferation jari group; (C) CFSE-DA proliferation lymphocytes positive control
(inset – dot plot representative); (D) Histograms represent the flow cytometric of CFSE-DA proliferative assay analyzes the proliferation of B16F10
melanoma cells after exposed to jara and jari toxins. All the experiments were repeated three times. Data are expressed as means ± SD. The statistical
difference was obtained between control group non treated and toxins groups.
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B16F10 cells
Jara and jari were comparatively used in order to elucidate
the role of the disintegrin domain of these toxins on the
effects induced in tumor cells. The morphological effects
on B16F10 cells were dose and time-dependent. These ef-
fects included loss of cytoplasm expansions, aggregates of
round shaped cells, and detachment from the bottom of
flasks, as shown by light microscopy similar to previous
findings in SK-Mel-28 human MM cells [21,28].
Through SEM it was possible to reveal additional mor-
phological details such as apoptotic and necrotic cells.
Numerous membranes blebbings were induced by jara,
whereas a decrease in cells density was observed withjari, which also changed the length and shape of the
microvilli, caused shrinkage of cell volume, increased the
number of apoptotic bodies and dispersed aggregates of
the supernatant (Figure 4).Effect of toxins treatment on caspase-3 activity
Caspase-3 activation contributes to DNA fragmentation
and morphological changes of cells. Flow cytometry ana-
lysis showed that jara and jari increased significantly
caspase-3 activity in B16F10 cells. Treatments with 0.4,
0.8, and 1.2 μM jara induced caspase-3 activity on 43 ±
6.8%, 60 ± 6.5% and 77 ± 8.2% cells, respectively (***p <
0.001). In contrast, jari (0.1, 0.2 and 0.4 uM) increased the
Figure 4 Morphological features of B16F10 cells exposed to toxins. The morphology of tumor cells was dramatically altered by toxin
treatments, as observed by light microscopy. Scanning electron microscopy (SEM) showed the melanoma cells grown as a large, spreading
monolayer, and the organization of the extracellular matrix with many protrusions. The cells showed retraction, and aggregates with 0.4 μM and
0.8 μM jara. Cells treated with jari showed detachment of the plate surface and formation of smaller aggregates (0.2 μM jari), and apoptotic
bodies and necrosis debris (0.4 μM jari). Magnification 400× (microscopy), scale bar 30 μm and 3 μm (SEM).
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tration. Further treatments with 0.8 and 1.2 uM jari (not
shown) killed most cells. Only 12.74 ± 2.2% untreated
cells, and about 20 ± 1.9% cells treated with chemotherapy
drug taxol (used as control) showed caspase-3 activity
(Figure 5).Analysis of apoptosis and cell cycle by flow cytometry
Jara significantly increased early and late apoptosis of
B16F10 cells. As shown in Figure 6A and B the number
of jara treated cells in apoptosis was significantly in-
creased (***p < 0.001) in a dose-dependent manner (0.4
and 0.8 μM), when compared to control cells. Contrarily,
Figure 5 Effects of toxins on caspase 3 active in B16F10 cells as evaluated by flow cytometry. Treatments induced significant increase of
caspase 3 active as compared to untreated cells or Taxol chemotherapeutic agent. Data were analyzed by the ANOVA one way variance test. The
results are representative mean ± SD of three independent experiments, *p < 0.05.
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(***p < 0.001) on jari treated cells (0.4 μM).
The distribution of populations in the cell cycle phases
was checked after jara and jari treatments. The percentage
of cells in G0/G1 phases was significantly reduced by both
toxins; the percentage of cells in S phase was significantly
decreased only with 0.4 μM jari treatment. No significant
alterations on the distribution of G2/M cells were induced
by both toxins. Sub-G1 cell populations (debris and frag-
mented DNA) were significantly increased after jara and
especially jari treatments (Figure 7).
Inhibition of metastases in mice injected with toxin-
treated B16F10 cells
B16F10 cells treated with 0.8 μM jara and 0.2 μM jari were
injected s.c. (5 × 104 cells/mice) in C57BL/6 J mice. Un-
treated tumor cells were injected in the control group.
Dorsal tumors were visualized in the injection site in all
animal groups (100%) after the tenth day. The mean
volume of dorsal tumors was significantly decreased in
animals injected with cells pretreated with jara or jari
(p = 0.0016) (Figure 8A). Dorsal tumor incidence was
smaller in animals injected with cells pretreated with
0.8 μM jara (80%), but was 100% both in controls and
the 0.2 μM jari group. After 40 days, the mean volume
of dorsal tumors in controls was 17.8 ± 4.5 mm3 for
control group; 5.8 ± 1.2 mm3 for 0.8 μM jara (p < 0.01),
and 3.4 ± 0.7 mm3 for 0.2 μM Jari (p < 0.001), i.e., it was
demonstrated a reduction in tumor volume of 67.5%
(jara) and 86.5% (jari) compared with tumors developed
by untreated B16F10 cells (Figure 8A, B). The survival
probability (Kaplan-Meier curve) was significantly in-
creased for animals injected with both jara and jari
treated cells (log rank p = 0.00218), (Figure 8C). The
long-rank test was used to test whether the differencebetween survival times between two groups: control X
jara; control X jari and jara X jari is statistically different.
Histopathological analysis of dorsal tumors induced by
B16F10 cells pretreated with jara showed leukocytes infil-
tration, areas of regression-like fibrosis, and few blood ves-
sels, as compared with controls (not shown).
The search for metastases was performed through
macroscopic analyses of internal organs like lung, liver,
spleen, kidney and lymph nodes. The number and volume
of metastases decreased significantly in animals injected
with jara and jari pre-treated cells (Table 1). The metasta-
sis nodules multiplicity was also significantly decreased to
12% and 6.8% when the injected cells were pre-treated
with jara or jari, respectively (Figure 8D).
Cell cycle of lung metastasis
Lung metastases induced by untreated and by jara and
jari-treated cells were isolated, the cells were dispersed
with collagenase type IV. A flow cytometric analysis re-
garding the DNA content of lung metastatic cells was
performed. The analysis of the distribution of metastatic
cells throughout the cell cycle phase suggested the in-
duction of metastasis was differently affected by jara and
jari pretreated tumor cells. The percentage of cells in
G0/G1 and of AND fragmented cells (sub-G1) was in-
creased, whereas an arrest of cells was found in S and
G2/M phases (Figure 8E).
Discussion
The search for anticancer agents has received a growing
biomedical interest, in particular regarding the effect of
native or isolated compounds found in snake venoms. The
ability of jara to interfere with cancer mechanisms had
already been investigated in SK-Mel-28 human MM cells
revealing important cytological alterations, as detachment
Figure 6 Analysis of apoptosis by flow cytometry. Induction of apoptosis in B16F10 cells by jara (0.4-0.8 μM) and jari (0.2-0.4 μM) for 24 h, as
shown through Annexin-V/PI double staining by flow cytometry. The representative dotplot adquisitions showed apoptotic cells and necrosis
areas (A). The apoptosis rate was estatistically significant for the percentage of early/late apoptotic cells after jara treatment, while jari showed
significant increase in the percentage of necrotic cells (B). Data represent mean ± SD of three independent experiments. *p < 0.05 and
***p < 0.001.
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retraction and formation of cell clusters in suspension.
The removal of the zinc ion from the metalloproteinase
domain of jara by the chelating agent 1,10-phenanthroline
caused a decrease in adhesion and viability of tumor cells
compared with the effects promoted by native jara [21].
The present study using murine, instead of human mel-
anoma cells, confirmed the above findings but at different
toxin concentrations showing that human amelanotic SK-
Mel-28 and the murine melanotic B16F10 cells have dif-
ferent sensibility to jara and jari treatments. Regarding the
in vivo experiments, Corrêa Jr. et al. [21] worked with
AIRmax and AIRmin mice, selected for high and low in-
flammatory response, whereas here C57BL/6 J mice were
tested. C57BL/6 J mice originated in 1974, from theJackson Laboratory, Bar Harbor, Maine, resistant develop-
ment tumor spontaneous.
This study was improved by several new approaches,
like the use of IC50 index for cells viability, and the inclu-
sion of ortho-phenantroline group of treated dorsal tumor
bearing mice. A clear distinction between increased apop-
tosis or necrosis was achieved by jara or jari treatments,
respectively. It is worthwhile to point that Tanjoni et al.
[29] demonstrated the induction of apoptosis (anoikis) in
endothelial cells treated with jara. This fact indicates the
caution as to the future use of jara or jari in the clinical
field.
The cell cycle in eukaryotes controls progression, be-
tween and within the phases, through checkpoints that
coordinate proliferation of the cells with the surrounding
Figure 7 Cell cycle analysis of B16F10 cells treated with jara and jari. Cells were stained with iodide propidium for DNA content analysis by
flow cytometry. The bars represent the proportions of G2/M proliferative cells; in phase S synthesis; G0/G1 quiescent cell, and debris in sub-G1.
The figure shows a significant decrease in the percentage of cells in G0/G1 phase and a subsequent increase in sub-G1 phase with increased
concentration of jara and jari. Data represents mean ± SD from three independent experiments. *Significantly different from control *p < 0.05;
**p < 0.01 and ***p < 0.001.
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replication and division [31].
In order to decipher the suppressive mechanisms of jara
and jari on B16F10 melanoma cells, we monitored the
changes in cell cycle distribution by cytometry flow
Toxin-treated cells showed increased sub-G1 populations,
reduced G0/G1 and S, and arrest in the G2/M phases. In
case of lung metastasis, most treated cells were arrest in
G0/G1 and decreased G2/M cells, an arrest of untreated
cells was observed.
Studies performed by ACTX-6, an L-amino acid oxi-
dase from A. acutus showed flow cytometry analysis it
could markedly increase accumulation of sub-G1 phase,
which suggested induce apoptosis [32]. A basic polypep-
tide with 60 amino acid residue CTX-III from Naja naja
atra venom exerts its specific anti-proliferative effects of
hepatocellular carcinoma cell (HepG2) via S phase cell
cycle arrest [32].
Measurement of cell proliferation with CFSE-DA of-
fers many advantages over conventional 3H-thymidine
incorporation assays. Labelling cells with CFSE-DA is a
simple procedure that eliminates use of radioactive ma-
terials and results in an extremely bright fluorescent sig-
nal that is easily detected by table top flow cytometers.
Intracellular esterase hydrolyses CFSE-DA into a fluores-
cent dye that binds covalently to cytoplasmic amino acid
residues such as lysine [33]; thus, only viable cells are la-
belled. However, labelled cells that die during the culture
period remain detectable until they disintegrate. Values
obtained with the proliferative rate determined by CSFE-
DA assay showed that effects on proliferative response
of B16F10 melanoma cells when treated with Jara and
Jari were similar to those results obtained by MTT assay.
Lymphocytes were labelled with CFSE-DA to be used as
control groups and were cultured for 96 h. After culture,the lymphocytes were harvested and analyzed. Cell div-
ision is characterized by sequential halving of CFSE
fluorescence, generating equally spaced peaks on a loga-
rithmic scale; peaks indicate the division cycle number.
Similar results of MTT colorimetric assay were obtained
using CSFE-DA methodology, which accurately con-
firmed proliferation rate of normal lymphocytes and
cytotoxic effects to B16F10 melanoma cells, in different
periods of treatment with jara and jari toxin.
The tumor proliferative rate decreases in proportion
as it grows, increasing the doubling time. Thus, tumors
have different doubling times at different times of their
growth/stage. Macroscopically we observed the presence
of areas of necrosis after 25 days of tumor growth, as
well as, proportion of cells in necrosis. In all periods
studied, there was an increase proliferative stage of cells
at the G2/M in metastasis lung after 15 and 25 days of
implantation.
The increased expression of the CASP3 gene, as mea-
sured by the caspase 3 protein fluorescence, confirmed
previous data obtained by RT-PCR [28]. As a whole,
those data point to a reduction of B16F10 cells prolifera-
tion attributed to jara and jari treatments. According to
Baldo et al. [34], jara induces detachment and decrease
the viability of human umbilical vein endothelial cells
(HUVEC), at similar concentrations for SK-Mel-28 cells,
while C2C12 myotube cells are more resistant to jara
under the same conditions.
Most snake venom disintegrins containing a disintegrin-
like/cystein-rich domain do not exhibit strong anti-
proliferative activity. However, jara and jari showed
anti-proliferative activity, besides decreased viability and
detachment. SEM confirmed the ability of jara and jari to
provoke detachment and apoptosis (jara) and necrose
(jari) in B16F10 cells. Furthermore, inhibition of the
Figure 8 Inhibition of tumor growth and metastasis dorsal treated with jara toxins and jari. C57/Bl6J mice were administered via
subcutaneous with B16F10 melanoma cells pretreated with 0.8 μM jara, 0.2 μM jari, and with untreated cells (control group). The growth curve
(A) and macroscopic aspect of the melanoma dorsal tumor of the control and treated groups (B) are shown, as well as the Kaplan-Meier survival
curve (C), metastasis multiplicity (D) and cell cycle phase of lung metastasis (E). Pre-treatment of tumor cells in vitro with jara or jari reduced the
dorsal tumor volume of B16F10 melanoma cells, with statistically significant increase in survival rates with p < 0.05 (Log rank p < 0.018). The number of
nodules in lung parenchyma was reduced on jara and jari groups. The distribution of cell cycle phase showed increase of tumor cells in
sub-G1, fragmented DNA and decreased number of cells in proliferative response arrest in G2/M, caused by jara and jari on metastasis lung.
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tumor effects, suggesting the disintegrin-like/cystein-rich
domains to be most important for the anti-proliferative ef-
fect. An alternative approach to this study was the pre-
treatment of B16F10 cells with jara and jari in order to
evaluate the toxin effect in vitro on the adhesion process.
Again, it was observed that jari was more effective to in-
hibit adhesion than jara (not shown). These results
reinforce the importance of the disintegrin-like domain of
jararhagin for the adhesion inhibition, rather than theproteolytic activity of the catalytic domain. Accordingly,
Costa and Santos [19] suggested the importance of the ac-
tive catalytic domain of jara for normal cells migration,
but not for adhesion. The apoptotic effect of jara and jari
was further confirmed by the analysis of expression of cas-
pase 3, the main apoptotic marker. Decrease in viability
and adhesion of B16F10 cells was accompanied by en-
hanced expression of caspase-3. Once activated, caspase-3
targets specific substrates, such as actin and nuclear
lamin A, and leads to DNA fragmentation, chromatin
Table 1 Dorsal tumors and metastases induced in C57BL/6
after toxin treated B16-F10 murine melanoma cells
Control 0.8 μM JARA 0.2 μM JARI
Total n° mice 10 10 10
Dorsal tumor
Incidence 10/10 (100%) 8/10 (80%) 10/10 (100%)


















1- Lung 42 (72.4%) 02 (28.5%) 03 (75%)
2- Liver 01 (1.7%) 01 (14.2%) 0
3- Spleen 01 (1.7%) 01 (14.2%) 0
4- Kidney 05 (8.6%) 0 0
5- Lymph nodes 09 (15.5%) 03 (42.8%) 01 (25%)
Total n° nodules 58 07**p < 0.01 04***p < 0.001
87.2% 93.1%
*The probabilities were compared to control values (Student unpaired T test;
Fisher’s – Yates exact tests).
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apoptotic effect of jara had already been observed on
SK-Mel-28 human cells [21]; on tEnd murine endothe-
lial [29] and HUVEC cells [34]. Contrarily to the effects
induced by jara, and especially jari, on SK-Mel-28 and
on B16F10 cells (this study), no morphological changes
were detected when normal endothelial cells were
treated with EDTA-inactivated jara [29]. The inactivation
of the proteolytic domain of jararhagin would better fit
the binding of the disintegrin/cystein rich domains to in-
tegrin receptors, improving signal transduction pathways
[20]. These data suggest that the cytotoxic activity of jara
and jari on the B16F10 cells are due to mechanisms other
than direct cytolytic effect, but the exact mechanism is
not yet clearly understood. Lipps [35] suggested that
venoms act directly on tumor cells causing their lysis,
whereas Markland et al. [36] proposed they act indirectly
by destroying the microenvironment produced by the
tumor cells. The present in vitro study shows that jara
induces apoptosis and causes DNA fragmentation by
activation of caspase-3, while jari induces necrosis and
decreased proliferative response, in B16F10 melanoma
cells.
Tumor metastasis is a dynamic process during which a
number of complex interactions occur between tumor
cells and the host. Metastasis causes the majority of mor-
bidity and mortality associated with melanoma. The lungsare one of the most common sites of melanoma cell dis-
semination. Tumor progression and metastasis depends
on factors that are intrinsic to tumor cells; on the extracel-
lular matrix proteins organization; proteases; chemokines
release; and cellular adhesion molecules [37]. Disintegrins
are potent inhibitors of integrin-ligand interactions. SK-
Mel-28 cells pre-treated with jara, and subsequently
injected in mice selected for anti-inflammatory response
significantly reduced the number of lung metastases [21].
In the present study, the decreased tumor volume, and
the increased number of treated cells in G0/G1 and arrest
in G2/M cell cycle phases observed in lung metastatic
cells, can be considered important markers of reduced
tumor burden and enhanced lifespan of mice bearing
B16F10 cells. The incidence of metastasis was also signifi-
cantly reduced in animals injected with B16F10 cells pre-
treated with 0.8 μM jara (12.1%) or 0.2 μM jari (6.9%), as
compared with controls. Reduction in metastasis inci-
dence had already been observed using SK-Mel-28 cells
pretreated with 0.8 μM jara (42.8%) or 0.2 μM jari (30.7%),
as compared with controls (83.3%), that had been injected
in mice genetically selected for acute inflammatory re-
sponse [38]. The main implication elicited from all studies
is the antiproliferative properties of jara, attributed to its
disintegrin domain, and the proliferation arrest in vivo.
Assuming its medical relevance, it is important to get a
better understanding of the mechanism of jara through
the evaluation of gene expression profiles induced on
tumor or normal cells after toxin binding and activation
of integrin transduction signals. The reduction on inci-
dence of nodules, the antiproliferative and antimetastatic
effects induced by jara and jari strengthen the potential
use of jararhagin as an anti-neoplastic drug.
Conclusion
Inhibitory concentration IC50 obtained showed that Jara
and Jari showed significant cytotoxicity in the tumor cell
line B16F10 murine melanoma; Jari concentration of
0.4 mM was shown to be capable of inducing senescence
population of cell cycle arrest leading to proliferation cell.
Treatment with Jara and Jari toxins showed antiprolifera-
tive activity, decreased viability and adherence, and show
that Jara induces apoptosis and causes DNA fragmenta-
tion through the activation of caspase-3, while Jari induces
necrosis and decreased proliferative response in B16F10
melanoma cells. The values obtained with the proliferation
rate determined by CSFE-DA assay showed that the effect
on the proliferative response of B16F10 melanoma cells
when treated with toxins corroborate the results obtained
by MTT assay. In vivo treatment of the toxins was ob-
served reduction in the incidence of nodules, and anti-
metastatic and antiproliferative effects in tumors. This
data strengthens the potential use jararhagin as an
anti-neoplastic drug.
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